Clinical Trials in Quimper, France
1 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 2
Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
NSCLC Stage IV
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 3
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Breast Cancer
UNICANCER3,902 enrolled70 locationsNCT07237256
Recruiting
Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Pfizer714 enrolled315 locationsNCT06758401
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca744 enrolled302 locationsNCT06417814
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
AstraZeneca4,300 enrolled727 locationsNCT05774951
Recruiting
Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
AstraZeneca860 enrolled264 locationsNCT05211895
Recruiting
Phase 2
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Metastatic CancerAdvanced CancerMalignant Neoplasm of Lung
Mirati Therapeutics Inc.200 enrolled120 locationsNCT05853575
Recruiting
Phase 3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca1,800 enrolled409 locationsNCT06120491
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics1,600 enrolled244 locationsNCT05899608
Recruiting
Phase 4
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
GFPC Investigation500 enrolled41 locationsNCT06646471
Recruiting
Phase 2
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
UNICANCER354 enrolled44 locationsNCT06078384
Recruiting
Not Applicable
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Groupe Francais De Pneumo-Cancerologie30 enrolled18 locationsNCT06247826
Recruiting
Phase 2
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
Breast Cancer Stage II
SOLTI Breast Cancer Research Group1,100 enrolled51 locationsNCT05296746
Recruiting
Phase 3
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Prostate Cancer Metastatic
UNICANCER300 enrolled90 locationsNCT04916613
Recruiting
Phase 2
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Large Cell Neuroendocrine Carcinoma of the Lung
Centre Leon Berard80 enrolled31 locationsNCT06393816